亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

濟南偉都化工有限公司  

醫藥原料藥和醫藥中間體

搜索
新聞中心
產品分類
  • 暫無分類
聯系方式
  • 聯系人:姚銳
  • 電話:0531-88873471
  • 郵件:wedochem@gmail.com
  • 傳真:0531-88873470
  • QQ:1783747865
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 鹽酸莫昔普利 82586-52-5
鹽酸莫昔普利 82586-52-5
單價 面議對比
詢價 暫無
發貨 山東濟南市付款后3天內
品牌 偉都化工
型號 82586-52-5
規格 99%
過期 長期有效
更新 2013-11-25 11:40
 
詳細信息

鹽酸莫昔普利  82586-52-5

英文名  Moexipril hydrochloride
別名  (3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid hydrochloride
產品名稱  鹽酸莫昔普利; 莫昔普利鹽酸鹽; (3S)-2-[(2S)-2-[[(1S)-1-(乙氧羰基)-3-苯基丙基]氨基]-1-氧代丙基]-1,2,3,4-四氫-6,7-二甲氧基-3-異喹啉羧酸鹽酸鹽
 
分子式  C27H34N2O7.HCl
分子量  535.03
CAS 登錄號  82586-52-5

©2025 濟南偉都化工有限公司 版權所有   技術支持:化工網   訪問量:22755  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |